Latest news with #FAP
Malaysian Reserve
4 days ago
- Business
- Malaysian Reserve
FAP Inhibitors Market Analysis Across the 7MM: Key Insights and Outlook Through 2040
According to DelveInsight's analysis, the growth of the FAP inhibitor market is expected to be primarily driven by the anticipated launch of several emerging therapies such as [18F] FAPI-74, [68Ga] FAPI-46, AZD2389, BXCL701, AVA6000, and others targeting a range of indications. LAS VEGAS, Aug 7, 2025 /PRNewswire/ — DelveInsight's FAP Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as NSCLC, Ovarian cancer, Pancreatic cancer, Metastatic colorectal cancer, Prostate cancer, Triple-negative breast cancer, Soft tissue sarcoma, and others. The selected indications are based on approved therapies and ongoing pipeline activity. The report also provides insights into the emerging FAP inhibitors, market share of individual therapies, and current and forecasted market size from 2020 to 2040, segmented into 7MM. Key Takeaways from the FAP Inhibitors Market Report As per DelveInsight's analysis, the total market size of FAP inhibitors in the 7MM is expected to surge significantly by 2040. The report provides the total potential number of patients in the indications, such as NSCLC, Ovarian cancer, Pancreatic cancer, Metastatic colorectal cancer, Prostate cancer, Triple-negative breast cancer, Soft tissue sarcoma, and others. Leading FAP inhibitor companies, such as SOFIE, BioXcel, OnkosXcel, AstraZeneca, Avacta, and others, are developing novel FAP inhibitors that can be available in the FAP inhibitors market in the coming years. Some of the key FAP inhibitors in the pipeline include [18F]FAPI-74, [68Ga]FAPI-46, BXCL701, AZD 2389, AVA6000, and others. In March 2025, Avacta announced promising early efficacy and safety data for AVA6000 in the Phase Ia Dose Escalation and ongoing enrollment in the Phase Ib Expansion Cohorts. In February 2024, BioXcel Therapeutics received US FDA Fast Track Designation for BXCL701 in combination with a checkpoint inhibitor (CPI) for the treatment of patients with metastatic small cell neuroendocrine prostate cancer (SCNC) with progression on chemotherapy and no evidence of microsatellite instability. Discover which indication is expected to grab the major FAP inhibitors market share @ FAP Inhibitors Market Report FAP Inhibitors Market Dynamics The FAP inhibitors market is gaining momentum as the understanding of FAP's role in various pathological conditions, particularly cancer and fibrosis, continues to evolve. FAP is highly expressed in cancer-associated fibroblasts (CAFs) within the tumor microenvironment and in fibrotic tissues, but is largely absent in normal adult tissues. This selective expression profile has made FAP an attractive target for therapeutic intervention, as it allows for more precise targeting of tumor stroma or fibrotic lesions with reduced off-target effects. As a result, the FAP inhibitor landscape is witnessing increased research and development activities from both pharmaceutical companies and academic institutions. Market growth is being fueled by multiple clinical programs evaluating FAP inhibitors in oncology, particularly in solid tumors such as pancreatic, breast, lung, and colorectal cancers. These inhibitors are being studied both as monotherapies and in combination with other agents like immune checkpoint inhibitors and chemotherapeutics. Several radiolabeled FAP inhibitors are also advancing in the diagnostics space, especially in PET imaging, offering real-time assessment of tumor burden and stromal activity. The dual diagnostic and therapeutic potential (theranostics) of FAP-targeting agents enhances their market appeal, with companies seeking to develop companion diagnostics and targeted radioligand therapies. Despite the promising potential, challenges persist in optimizing the pharmacokinetics, safety profiles, and therapeutic windows of FAP inhibitors. Many compounds in development are still in early- to mid-stage clinical trials, and efficacy data remain limited. Additionally, while FAP overexpression is common across various tumors, patient stratification and biomarker-driven approaches will be critical for successful commercialization. Addressing these challenges through improved drug design and clinical validation will be key to unlocking the full potential of this drug class. From a competitive standpoint, the market is moderately fragmented, with a mix of biotech startups and large pharmaceutical companies pursuing differentiated approaches. Some developers are focusing on small molecules, while others are leveraging antibody-drug conjugates (ADCs), bispecific antibodies, or FAP-targeted radiopharmaceuticals. Strategic collaborations, licensing deals, and academic partnerships are becoming common, as companies seek to access novel platforms and reduce development risk. This dynamic landscape suggests significant potential for innovation, particularly in niche indications where conventional therapies have limited efficacy. In the coming years, the FAP inhibitors market is expected to benefit from growing interest in tumor microenvironment modulation, expanding applications in fibrotic diseases, and increased investment in precision medicine. Regulatory pathways for novel cancer and fibrosis therapeutics continue to evolve, potentially accelerating time-to-market for promising FAP-targeted agents. With no approved therapies currently available, the first entrants into the market stand to capture substantial value, especially if they demonstrate meaningful clinical benefit in underserved patient populations. FAP Inhibitors Treatment Market FAPI belongs to a novel class of tracers with emerging roles in cancer diagnosis and therapy. Clinical trials are actively investigating the safety and efficacy of FAP inhibitors for both oncologic and fibrotic conditions, with several candidates advancing into mid-stage trials. Currently, no FAP inhibitors have received regulatory approval. While challenges remain, such as enhancing drug delivery and reducing toxicity, FAP-targeted therapies represent a promising step forward in precision treatment for cancer and fibrotic diseases. Continued research and clinical validation could position FAP inhibitors as an innovative option for patients with these complex conditions. FAP has gained recognition as a specific biomarker for carcinoma-associated fibroblasts (CAFs) and activated fibroblasts found in tissues undergoing extracellular matrix (ECM) remodeling due to persistent inflammation, fibrosis, or tissue repair. FAPI agents have been studied extensively across multiple tumor types, in both diagnostic imaging and therapeutic applications. The tumor microenvironment (TME), predominantly consisting of ECM components like blood vessels, cytokines, growth factors, and fibroblasts, plays a central role in cancer development. Fibroblasts contribute to collagen synthesis and modulate local inflammatory and homeostatic processes. A specialized subgroup, myofibroblasts, exhibits contractile features similar to smooth muscle cells. In colorectal cancer, FAP overexpression in fibroblasts has been associated with poor prognosis, including increased lymph node involvement, tumor recurrence, angiogenesis, and decreased overall survival. Learn more about the FAP inhibitors @ FAP Inhibitors Analysis Key Emerging FAP Inhibitors and Companies Key players in the FAP inhibitor market include AstraZeneca (AZD 2389), Sofie ([18F]FAPI-74; [68Ga]FAPI-46), BioXcel/OnkosXcel (BXCL701), Avacta Life Science (AVA6000), and several other companies. A radiopharmaceutical known as [18F] FAPI-74 combines FAPI-74, a quinoline-based compound that targets fibroblast activation protein (FAP), with the chelating agent NOTA (1,4,7-triazacyclononane-N,N',N'-triacetic acid), and is labeled with the positron-emitting isotope fluorine-18. It is designed for PET imaging of tumors and cancer-associated fibroblasts (CAFs) that express FAP. After administration, FAPI-74 binds to FAP-expressing tumor cells and CAFs. These bound cells can then be visualized via PET scans. FAP is a surface protein highly expressed in many cancers and in CAFs within the tumor microenvironment (TME). A Phase II clinical trial (NCT05641896) is underway to evaluate [18F] FAPI-74 PET imaging in patients with gastrointestinal cancers. This study is multicenter, single-arm, open-label, and non-randomized. In October 2023, SOFIE and GE HealthCare entered into a licensing agreement for the development and commercialization of [68Ga] FAPI-46 and [18F] FAPI-74. Under this deal, GE HealthCare acquired global rights to [68Ga] FAPI-46 and ex-U.S. rights to [18F] FAPI-74, while SOFIE retained U.S. rights for [18F] FAPI-74's clinical development and commercialization. AVA6000, a prodrug of the chemotherapy agent doxorubicin, functions by inhibiting an enzyme that promotes cancer cell growth. Unlike standard doxorubicin, AVA6000 remains inactive until it reaches tumor tissue, potentially reducing side effects. It is administered intravenously. On January 16, 2025, Avacta reported encouraging results from its Phase I trial of AVA6000. In patients with salivary gland cancer, five out of ten showed tumor shrinkage—ranging from partial to minor responses—with a disease control rate of 90%. The anticipated launch of these emerging therapies are poised to transform the FAP inhibitors market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the FAP inhibitors market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. To know more about FAP inhibitors clinical trials, visit @ FAP Inhibitors Treatment FAP Inhibitors Overview Fibroblast activation protein (FAP) is a type II transmembrane serine protease predominantly found on activated fibroblasts, especially within the tumor microenvironment and areas of tissue remodeling. It is largely absent in healthy adult tissues but becomes markedly upregulated in more than 90% of epithelial cancers, where it plays a key role in promoting tumor progression by remodeling the extracellular matrix, supporting angiogenesis, suppressing immune responses, and aiding tumor cell invasion. Elevated levels of FAP are also observed in various fibrotic and inflammatory conditions, including liver cirrhosis, pulmonary fibrosis, rheumatoid arthritis, and during wound healing, emphasizing its broader involvement in pathological tissue remodeling. Because of its disease-restricted expression and functional significance, FAP has gained traction as a target for diagnostic and therapeutic applications. Radiolabeled FAP inhibitors (FAPIs) have delivered strong results in PET imaging by offering high-contrast visualization of tumors and fibrotic tissues with minimal background interference. These promising outcomes have led to the development of FAP-targeted treatments such as radioligand therapies, antibody-drug conjugates, and CAR T-cell approaches designed to modulate the tumor stroma and boost anti-cancer activity. Nevertheless, challenges remain, particularly in achieving specificity over related proteases and managing potential side effects in fibrotic conditions. Current research efforts are focused on optimizing FAPI pharmacokinetics, enhancing therapeutic effectiveness, and evaluating synergistic strategies with immunotherapies. Notably, FAP-targeted imaging and treatment approaches are expanding beyond oncology into fields like cardiology, pulmonology, and autoimmune disease, underscoring its growing importance as a biomarker and therapeutic target with the potential to transform precision medicine for both cancer and fibrotic disorders. FAP Inhibitors Epidemiology Segmentation The FAP inhibitors market report proffers epidemiological analysis for the study period 2020–2040 in the 7MM, segmented into: Total Cases in Selected Indications for FAP Inhibitor Total Eligible Patient Pool in Selected Indications for FAP Inhibitor Total Treated Cases in Selected Indications for FAP Inhibitor FAP Inhibitors Report Metrics Details Study Period 2020–2040 FAP Inhibitors Report Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] Key Indications Covered in the Report NSCLC, Ovarian cancer, Pancreatic cancer, Metastatic colorectal cancer, Prostate cancer, Triple-negative breast cancer, Soft tissue sarcoma, and others Key FAP Inhibitors Companies SOFIE, BioXcel, OnkosXcel, AstraZeneca, Avacta, and others Key FAP Inhibitors [18F]FAPI-74, [68Ga]FAPI-46, BXCL701, AZD 2389, AVA6000, and others Scope of the FAP Inhibitors Market Report FAP Inhibitors Therapeutic Assessment: FAP Inhibitors' current marketed and emerging therapies FAP Inhibitors Market Dynamics: Conjoint Analysis of Emerging FAP Inhibitor Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, FAP Inhibitors Market Access and Reimbursement Discover more about FAP inhibitors in development @ FAP Inhibitors Clinical Trials Table of Contents 1. Key Insights 2. Report Introduction 3. Executive Summary of FAP Inhibitor 4. Key Events 5. Epidemiology and Market Forecast Methodology 6. FAP Inhibitor Market Overview at a Glance in the 7MM 6.1. Market Share (%) Distribution by Therapies in 2024 6.2. Market Share (%) Distribution by Therapies in 2040 6.3. Market Share (%) Distribution by Indications in 2024 6.4. Market Share (%) Distribution by Indications in 2040 7. FAP Inhibitor: Background and Overview 7.1. Introduction 7.2. Potential of FAP Inhibitor in Different Indications 7.3. Clinical Applications of FAP Inhibitor 8. FAP Target Patient Pool 8.1. Key Findings 8.2. Assumptions and Rationale: 7MM 8.3. Epidemiology Scenario in the 7MM 8.4. Total Cases in Selected Indications for FAP Inhibitor in the 7MM 8.5. Total Eligible Patient Pool for FAP Inhibitor in Selected Indications in the 7MM 8.6. Total Treated Cases in Selected Indications for FAP Inhibitor in the 7MM 9. Emerging Therapies 9.1. Key Competitors 9.2. [ F]FAPI-74: SOFIE 9.2.1. Product Description 9.2.2. Other developmental activities 9.2.3. Clinical development 9.2.4. Safety and efficacy 9.2.5. Analyst Views 9.3. AVA6000: Avacta List to be continued in the report 10. FAP Inhibitor: Seven Major Market Analysis 10.1. Key Findings 10.2. Market Outlook 10.3. Conjoint Analysis 10.4. Key Market Forecast Assumptions 10.4.1. Cost Assumptions and Rebates 10.4.2. Pricing Trends 10.4.3. Analogue Assessment 10.4.4. Launch Year and Therapy Uptakes 10.5. Total Market Size of FAP Inhibitor in the 7MM 10.6. Market Size of FAP Inhibitor by Indication in the 7MM 10.7. The United States 10.8. EU4 and the UK 10.9. Japan 11. Market Access and Reimbursement 12. SWOT Analysis 13. KOL Views 14. Unmet Needs 15. Bibliography 16. Report Methodology Related Reports Prostate Cancer Market Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key prostate cancer companies, including Janssen Research and Development, Sanofi, Astellas Pharma, Bayer, Novartis, Curium, Merck, Orion, Pfizer, Exelixis, Ipsen Pharma, Takeda, AB Science, Lantheus, Eli Lilly, POINT Biopharma, Telix Pharmaceuticals, Tavanta Therapeutics, Jiangsu Hengrui Pharmaceuticals, Kangpu Biopharmaceuticals, Fusion Pharma, Merus, Bristol-Myers Squibb, Syntrix Pharmaceuticals, Promontory Therapeutics, Xencor, Taiho Pharmaceutical, Madison Vaccines, MacroGenics, Zenith Epigenetics, Modra Pharmaceuticals, Arvinas, Laekna Therapeutics, Blue Earth Therapeutics, Oncternal Therapeutics, Essa Pharma, Clarity Pharmaceuticals, BioNTech and DualityBio, Daiichi Sankyo, Fortis Therapeutics, ORIC Pharmaceuticals, Amgen, among others. Non-Small Cell Lung Cancer Market Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NSCLC companies, including AstraZeneca, Boehringer Ingelheim, Takeda, Johnson & Johnson Innovative Medicine, Eli Lilly and Company, Merck, Bristol-Myers Squibb, Roche, Shanghai Henlius Biotech, AbbVie, Daiichi Sankyo, Nuvation Bio, PDC*line Pharma, Moderna Therapeutics, Pfizer, GSK, Gilead Sciences, BieGene, Nuvalent, among others. Metastatic Colorectal Cancer Market Metastatic Colorectal Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key metastatic colorectal cancer companies, including Johnson & Johnson Innovative Medicine, Shanghai Henlius Biotech, Inspirna, Treos Bio, Cardiff Oncology, Agenus, Leap Therapeutics, Arcus Biosciences, Enterome, Tizona Therapeutics, Innovative Cellular Therapeutics, among others. Pancreatic Cancer Market Pancreatic Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key pancreatic cancer companies, including AstraZeneca, Merck Sharp & Dohme LLC, Bayer, Roche, Celgene, BioLineRx, Alligator Bioscience, Bellicum Pharmaceuticals, OSE Immunotherapeutics, Actuate Therapeutics, FibroGen, NeoImmuneTech, NOXXON Pharma, Silenseed Ltd., Amgen, NGM Biopharmaceuticals, Merus, Mirati Therapeutics, Rexahn Pharmaceuticals, Ocuphire Pharma, Processa Pharmaceuticals, ImmunityBio, Berg, Panbela Therapeutics, GlaxoSmithKline, Eleison Pharmaceuticals, Molecular Templates, Lokon Pharma AB, Cantargia AB, Bristol-Myers Squibb, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Contact UsShruti Thakur info@ +14699457679 Logo: View original content:
India Today
31-07-2025
- Health
- India Today
Medical colleges rise from 387 to 780, doctor-population ratio at 1:811, says JP Nadda
India has witnessed a significant expansion in medical education infrastructure over the past decade. The number of medical colleges has increased from 387 in 2014 to 780 in 2024, Union Health Minister J P Nadda told the Rajya Sabha on minister said undergraduate seats have gone up from 51,348 to 1,15,900, and postgraduate seats have risen from 31,185 to 74,306 during the same surge is aimed at enhancing the availability of trained medical professionals in the RATIO IMPROVES TO 1:811 Responding to a question on the doctor-population ratio, Nadda said India currently has 13.86 lakh registered allopathic doctors and 7.51 lakh registered AYUSH that 80 per cent of these are active in practice, the doctor-to-population ratio is estimated to be 1:811, better than the WHO recommended 1: also emphasised that healthcare delivery falls under state jurisdiction. However, the central government continues to assist states and union territories by offering support through schemes, funding, and infrastructure HEALTHCARE BOOSTED THROUGH STUDENT OUTREACHThe government has also taken steps to strengthen healthcare in rural areas through the Family Adoption Programme (FAP).Under this initiative, medical colleges adopt villages, and MBBS students adopt families to provide basic healthcare support. The programme aims to promote vaccination, nutrition, hygiene, and awareness about government health the District Residency Programme (DRP) mandates a three-month posting for PG students at district hospitals, giving them exposure to rural healthcare needs while boosting services in underserved AROGYA MANDIRS TRANSFORM PRIMARY CARE ACCESSAs of July 15, 2025, a total of 1,78,154 Ayushman Arogya Mandirs (AAMs) have been established by converting Sub-Health Centres (SHCs) and Primary Health Centres (PHCs) into hubs of comprehensive primary centres now offer 12 healthcare packages, significantly expanding the scope beyond maternal and child said annual footfall at these facilities has jumped from 13.49 crore in 2019-20 to 128.08 crore in 2024-25. Over 117 crore people have been screened for non-communicable diseases such as hypertension, diabetes, and various services and improved medical availability at AAMs have further addressed healthcare gaps, particularly in rural and remote areas.- Ends
News18
30-07-2025
- Health
- News18
Medical Colleges Rose From 387 In 2014 To 780 Now: Health Ministry To Rajya Sabha
Last Updated: Health Minister J P Nadda noted that public health is a state subject, and state govts are responsible for engaging available medical professionals in various healthcare setups. Since 2014, the number of medical colleges has increased from 387 to 780, undergraduate seats have risen from 51,348 to 1,15,900, and postgraduate seats have grown from 31,185 to 74,306, as Union Health Minister J P Nadda informed the Rajya Sabha on Tuesday. Answering a question, Nadda mentioned the government's efforts to increase the number of medical colleges and both undergraduate (UG) and postgraduate (PG) seats, reported PTI. Currently, there are 13,86,157 registered allopathic doctors and 7,51,768 registered practitioners in the AYUSH system of medicine. The World Health Organisation (WHO) recommends a doctor-to-population ratio of 1:1000. 'Assuming that 80 percent of registered practitioners in both the allopathic and AYUSH systems are available, the estimated doctor-population ratio in the country is 1:811," Nadda said. Nadda noted that public health is a state subject, and state governments are responsible for engaging available medical professionals in various healthcare setups, the PTI report added. To bridge healthcare delivery gaps, the government supports states and UTs through various central sector and centrally sponsored schemes/programmes. This support includes financial assistance, capacity building, provision of essential medicines, diagnostics, teleconsultation services, etc., to ensure effective and accessible primary healthcare. The Family Adoption Programme (FAP) has been integrated into the MBBS curriculum to provide equitable healthcare access to rural populations. The FAP involves medical colleges adopting villages and MBBS students adopting families within these villages. This enables regular follow-ups for vaccination, growth monitoring, menstrual hygiene, Iron and Folic Acid (IFA) supplementation, healthy lifestyle practices, nutrition, vector control, and medication adherence, according to the minister. It also helps educate families about ongoing government health programmes. Additionally, the District Residency Programme (DRP), notified by the National Medical Commission (NMC), mandates a compulsory three-month posting and training of PG medical students at district hospitals as part of the course curriculum. The DRP strengthens healthcare delivery in rural and underserved areas. Since its launch in 2018, 1,78,154 Ayushman Arogya Mandirs (AAMs) have been established as of July 15 by transforming existing Sub-Health Centres (SHCs) and Primary Health Centres (PHCs) to provide comprehensive primary healthcare closer to people's homes. Services have expanded from basic maternal and child care to twelve comprehensive healthcare packages. With these reforms, annual footfall increased from 13.49 crore in the financial year 2019-20 to 128.08 crore in 2024-25. Over 117 crore individuals have been screened for hypertension, diabetes, oral, breast, and cervical cancers. The availability of medicines at AAMs and teleconsultations with specialists have enhanced accessibility, reduced costs, and addressed provider shortages, Nadda stated. First Published: News education-career Medical Colleges Rose From 387 In 2014 To 780 Now: Health Ministry To Rajya Sabha Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Time of India
30-07-2025
- Health
- Time of India
Medical colleges increased from 387 in 2014 to 780
New Delhi: The number of medical colleges increased from 387 to 780, undergraduate seats from 51,348 to 1,15,900 and postgraduate seats from 31,185 to 74,306 since 2014, Union Health Minister J P Nadda told the Rajya Sabha on Tuesday. Responding to a question, Nadda said that the government has increased the number of medical colleges, under graduate (UG) and post graduate (PG) seats. There are 13,86,157 registered allopathic doctors and 7,51,768 registered practitioners in the AYUSH system of medicine. The World Health Organisation (WHO) recommends a doctor to population ratio of 1:1000. "Assuming that 80 per cent of registered practitioners in both the allopathic and AYUSH systems are available, the doctor-population ratio in the country is estimated to be 1:811," Nadda said. Nadda said that public health is a state subject and the matter regarding engagement of available medical professionals in the country in various healthcare setups comes under the purview of state governments. However, to bridge healthcare delivery gaps, the government continues to support states and UTs through various central sector/centrally sponsored schemes/programmes by providing financial assistance, capacity building, provision of essential medicines, diagnostics, teleconsultation services, etc. to ensure effective and accessible primary healthcare. The Family Adoption Programme (FAP) has been incorporated into the MBBS curriculum to provide equitable healthcare access to rural population, Nadda said. The FAP involves medical colleges adopting villages, and MBBS students adopting families within these villages. This enables regular follow-up of adopted families for vaccination, growth monitoring, menstrual hygiene, Iron and Folic Acid (IFA) supplementation, healthy lifestyle practices, nutrition, vector control, and medication adherence, the minister said. It also helps in educating families about ongoing government health programmes, he said. Further, the District Residency Programme (DRP) notified by the National Medical Commission (NMC) provides for a compulsory three-month posting cum training of PG medical students at district hospitals as a part of the course curriculum. The DRP benefits the public by strengthening healthcare delivery in rural and underserved areas. Launched in 2018, 1,78,154 Ayushman Arogya Mandirs (AAMs) have been established as on July 15 by transforming existing Sub-Health Centres (SHCs) and Primary Health Centres (PHCs) to provide comprehensive primary healthcare closer to people's homes, Nadda said. Services have expanded from basic maternal and child care to twelve (12) comprehensive healthcare packages. With these reforms, annual footfall rose from 13.49 crore in the financial year 2019-20 to 128.08 crore in 2024-25. Over 117 crore individuals have been screened for hypertension, diabetes, oral, breast, and cervical cancers. Availability of medicines at AAMs and teleconsultations with specialists have improved accessibility, reduced costs, and addressed provider shortages, Nadda stated. PTI
Yahoo
30-07-2025
- Business
- Yahoo
Why Recursion Pharmaceuticals Stock Got Mashed on Monday
Key Points The company isn't the only developer of a drug for FAP, a rare genetic disease. A rival just reported that its own FAP treatment is advancing to late-stage testing. 10 stocks we like better than Recursion Pharmaceuticals › Clinical-stage biotech Recursion Pharmaceuticals' (NASDAQ: RXRX) stock took it on the chin in the first trading day of the week. Monday saw investors back out of the company's shares, leaving them with an almost 3% decline at market close. The benchmark S&P 500 (SNPINDEX: ^GSPC) did notably better, ticking up slightly on the day. A rival reports a major step forward This was largely due to news from a rival clincal-stage biotech. Late on Friday, U.K.-based Biodexa announced it had launched a phase 3 clinical trial of its eRapa, an investigational drug that targets familial adenomatous polyposis (FAP). This is a rare genetic disease which, when left untreated, typically leads to colorectal cancer. Biodexa has been granted Fast Track status for investigating the drug from the U.S. Food and Drug Administration (FDA). This followed a phase 2 clinical trial in which the drug met its primary endpoints. The advancement of eRapa puts it ahead of Recursion's REC-4881, which is also aimed at treating FAP. The company completed a phase 1b/2 study of the drug earlier this year. Like Biodexa's drug, REC-4881 did well in that stage of testing. The best should win As any seasoned biotech investor would attest, it's the final results and approval process of a drug that ultimately count. Given that, it's hardly encouraging that Biodexa has taken a big step forward ahead of Recursion in the development of its FAP medication. The latter company's investors will be hoping that REC-4881 ultimately proves to be the more efficacious drug for the disorder. Should you invest $1,000 in Recursion Pharmaceuticals right now? Before you buy stock in Recursion Pharmaceuticals, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Recursion Pharmaceuticals wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* Now, it's worth noting Stock Advisor's total average return is 1,041% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 28, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Recursion Pharmaceuticals Stock Got Mashed on Monday was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
